Answers are grounded in this paper and cite their sources.
Review highlights nitazoxanide's effectiveness against gastrointestinal infections in children and adults, suggesting its first-line status.
Nitazoxanide is a new thiazolide antiparasitic agent. Nitazoxanide (AliniaR, DaxonR, DexidexR, ParamixR, KidonaxR, ColufaseR, AnnitaR) has in vitro activity against a variety of microorganisms, including a broad range of protozoa and helminths. Nitazoxanide is effective in the treatment of protozoal and helminthic infections, including Cryptosporidium parvum or Giardia lamblia, in immunocompetent adults and children, and is generally well tolerated. Nitazoxanide is a firstline choice for the treatment of illness caused by C. parvum or G. lamblia infection in immunocompetent adults and children, and is an option to be considered in the treatment of illnesses caused by other protozoa and/or helminths. Nitazoxanide has been licensed for the treatment of Giardia intestinalis–induced diarrhea in patients 1 year of age and Cryptosporidum-induced diarrhea in children aged 1–11 years.
No takes yet. Share an insight, caveat, or question.
*Dr. Shruti Sarwade (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: